Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07566832

Velocity-Based Resistance Training Effects on Inflammation in Older Adults

This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Aging Inflammatory Response

Age range

60 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 60-75 years or older
  • No regular resistance training habit (defined as ≥2 sessions per week) in the past year
  • No musculoskeletal injuries within the past six months

Exclusion criteria

  • Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
  • Regular use of anti-inflammatory medications (e.g., NSAIDs).
  • Smoking or alcohol abuse
  • Inability to safely perform the prescribed resistance exercise movements
  • Unable to fully comprehend the study information and instructions.

Treatment and study plan

Resistance Exercise

Other

The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.

Primary outcomes

  1. Changes in IL-6 concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Plasma IL-6 concentrations will be measured and reported in pg/mL.

  2. Changes in soluble IL-6 receptor concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.

  3. Changes in soluble gp130 concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Soluble gp130 concentrations will be measured and reported in ng/mL.

  4. Changes in IL-10 concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    IL-10 concentrations will be measured and reported in pg/mL.

  5. Changes in IL-1RA concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    IL-1RA concentrations will be measured and reported in pg/mL.

  6. Changes in TNF-α concentration

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    TNF-α concentrations will be measured and reported in pg/mL.

Secondary outcomes

  1. Borgs Ratings of Perceived Exertion (RPE)

    Time frame: 1-hour during each exercise intervention

    Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).

  2. Handgrip strength

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.

  3. Knee extension strength

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.

  4. 30-second chair-stand test

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.

  5. Single-leg balance test

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Balance performance will be assessed as the duration of single-leg stance and reported in seconds.

  6. Timed up and go test

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.

  7. Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.

  8. Changes in gp130 (CD130) protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.

  9. Changes in STAT3 protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.

  10. Changes in phosphorylated STAT3 protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.

  11. Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.

  12. Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.

  13. Changes in SOCS3 protein expression in PBMCs

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.

  14. Changes in white blood cell count

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Total white blood cell count will be measured and reported in cells/μL.

  15. Changes in lymphocyte count

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Lymphocyte count will be measured and reported in cells/μL.

  16. Changes in neutrophil count

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Neutrophil count will be measured and reported in cells/μL.

  17. Changes in monocyte count

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Monocyte count will be measured and reported in cells/μL.

  18. Body fat percentage

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Body fat percentage will be measured using a body composition analyzer and reported as a percentage.

  19. Lean body mass

    Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

    Total lean body mass will be measured using a body composition analyzer and reported in kilograms.

Study contacts

Contact information is provided by the study sponsor or research team.

Shun-Hsi Tsai, Ph.D.

CONTACT

[email protected]

+88686741111 ext. 68523

Sponsors and collaborators

Lead sponsor

National Taipei University

Other

Registry information

Official study title

Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
May 5, 2026
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.